{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu P"],"funding":["Startup Fund for Scientific Research, Fujian Medical University","Fujian Provincial Natural Science Foundation of China","the Joint Funds for the Innovation of Science and Technology, Fujian province","Fujian provincial health technology project"],"pagination":["348"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12923716"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Background</h4>Oxaliplatin (OXA) resistance poses a significant challenge to the efficacy of chemotherapy for advanced colorectal cancer (CRC). This study aimed to elucidate the role of OXA in regulating Cysteine-rich protein 61 (Cyr61) expression via the Hippo-Yes-associated protein (YAP) pathway in the context of chemotherapy-induced drug resistance.<h4>Methods</h4>We used Cell Counting Kit-8 to detect cell viability and proliferation. Expression of Cyr61 was determined by quantitative real-time PCR, western blotting (WB) and Enzyme-linked immunosorbent assay in CRC cell lines. The mechanism of OXA in regulating Cyr61 expression was studied by WB and co-immunoprecipitation.<h4>Results</h4>The results revealed that exposure to varying concentrations of OXA for 24 h induced increased m"],"journal":["Discover oncology"],"pubmed_title":["Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells."],"pmcid":["PMC12923716"],"funding_grant_id":["2020Y9088","2021GGA015","2024J01596","2023QH1057"],"pubmed_authors":["Zhang J","Huang Z","Cao Y","Zheng C","Zhu X","Chen X","Lu P"],"additional_accession":[]},"is_claimable":false,"name":"Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.","description":"<h4>Background</h4>Oxaliplatin (OXA) resistance poses a significant challenge to the efficacy of chemotherapy for advanced colorectal cancer (CRC). This study aimed to elucidate the role of OXA in regulating Cysteine-rich protein 61 (Cyr61) expression via the Hippo-Yes-associated protein (YAP) pathway in the context of chemotherapy-induced drug resistance.<h4>Methods</h4>We used Cell Counting Kit-8 to detect cell viability and proliferation. Expression of Cyr61 was determined by quantitative real-time PCR, western blotting (WB) and Enzyme-linked immunosorbent assay in CRC cell lines. The mechanism of OXA in regulating Cyr61 expression was studied by WB and co-immunoprecipitation.<h4>Results</h4>The results revealed that exposure to varying concentrations of OXA for 24 h induced increased m","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-09T11:49:24.452Z","creation":"2026-07-09T11:02:21.765Z"},"accession":"S-EPMC12923716","cross_references":{"pubmed":["41606217"],"doi":["10.1007/s12672-026-04530-2"]}}